Melphalan flufenamide receives approval from the FDA for relapsed or refractory multiple myeloma

Share This Post

August 2021: Melphalan flufenamide (Pepaxto, Oncopeptides AB) in combination with dexamethasone has been granted accelerated approval by the Food and Drug Administration for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD-38 directed monoclonal antibody.

HORIZON (NCT02963493), a multicenter, single-arm trial, was used to assess efficacy. Patients had to have relapsed refractory multiple myeloma to be eligible. Patients received 40 mg of melphalan flufenamide intravenously on day 1 and 40 mg of dexamethasone orally on days 1, 8, 15, and 22 of each 28-day cycle until disease progression or intolerable toxicity.

Efficacy was assessed in a subset of 97 patients who had failed at least one proteasome inhibitor, one immunomodulatory drug, and a CD38-directed antibody and had had four or more prior lines of therapy. The overall response rate (ORR) and duration of response (DOR) were the primary efficacy outcomes measured by investigators using the International Myeloma Working Group (IMWG) Criteria. The ORR was 23.7 percent (95 percent confidence interval: 15.7 to 33.4), with a median DOR of 4.2 months (95 percent CI: 3.2, 7.6).

The 157 participants enrolled in HORIZON were examined for safety. Fatigue, nausea, diarrhoea, pyrexia, and respiratory tract infection are the most common side effects (> 20%). Decreased leukocytes, platelets, lymphocytes, neutrophils, and haemoglobin, as well as increased creatinine, are the most prevalent laboratory abnormalities (50 percent).

Melphalan flufenamide’s safety and efficacy as a conditioning regimen in transplant recipients has yet to be determined. Outside of controlled clinical trials, melphalan flufenamide is not indicated and is not recommended for use as a conditioning regimen for transplant, according to the USPI.

The recommended dose of melphalan flufenamide in conjunction with dexamethasone is 40 mg intravenously over 30 minutes on day 1 of each 28-day therapy cycle.

 

Reference : https://www.fda.gov/

Check details over here.

Take second opinion on multiple myeloma treatment


Send Details

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient A case report
CAR T-Cell therapy

Claudin18.2-targeted CAR-T cell therapy brings complete remission in advanced pancreatic cancer patient : A case report

Claudin18.2-targeted CAR-T cell therapy has shown remarkable potential in treating advanced pancreatic cancer, as highlighted in a recent case report. This innovative approach led to complete remission in a patient with advanced disease, underscoring the promise of targeted immunotherapy. By leveraging the specific expression of Claudin18.2 on cancer cells, this therapy offers a precision-based treatment, heralding a new era in pancreatic cancer management with significant clinical implications.

What is the treatment after BCMA CAR T failed in RR multiple myeloma cases
CAR T-Cell therapy

What is the treatment after BCMA CAR T failed in R/R multiple myeloma cases?

For people with relapsed or refractory multiple myeloma, BCMA CAR T-cell therapy might not work. Other treatments, such as bispecific antibodies, other CAR T-cell therapies that target different antigens, and combination regimens with immunomodulatory drugs, proteasome inhibitors, and monoclonal antibodies, can still be used. OriCAR-017 is another immunotherapy that is under trial and is expected to be launched soon. Clinical trials offer experimental treatments, providing access to novel therapies. Tailored approaches based on patient-specific factors and emerging research are crucial for improving outcomes in this challenging scenario.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) Cancer treatment abroad?
2) CAR T-Cell therapy
3) Cancer vaccine
4) Online video consultation
5) Proton therapy